Clinical Trials Logo

Severe Eosinophilic Asthma clinical trials

View clinical trials related to Severe Eosinophilic Asthma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06302959 Not yet recruiting - Clinical trials for Severe Eosinophilic Asthma

Clock Proteins as Prognostic Markers

CLOCK-PM
Start date: May 1, 2024
Phase:
Study type: Observational

Asthma is a chronic inflammatory disease of the airways that follows a strong circadian rhythm: Signs of inflammation and symptoms worsen especially in the early morning hours. The molecular circadian clock, which is a complex machinery of transcriptional and translational feedback loops, seems to reflect the inflammatory environment of peripheral blood leukocytes. Therefore, in this observational study the investigators will monitor the molecular circadian clock in patients with severe eosinophilic asthma before and during mepolizumab treatment. Our major goal is to evaluate the potential of the molecular circadian clock to serve as a prognostic marker for disease progression, treatment response or remission in patients with severe eosinophilic asthma. The molecular circadian clock will be monitored in blood and sputum leukocytes from patients with severe eosinophilic asthma before mepolizumab treatment, after 4 month of mepolizumab therapy, and once they reach remission under mepolizumab treatment. Effects will be compared to healthy controls and patients with mild-moderate asthma without mepolizumab treatment.

NCT ID: NCT03652376 Not yet recruiting - Clinical trials for Severe Eosinophilic Asthma

Impact of Benralizumab Treatment on Circulating Dendritic Cells in Patients With Eosinophilic Asthma

Start date: September 1, 2018
Phase: Phase 4
Study type: Interventional

This study investigates the effect of removing eosinophils from peripheral blood (using treatment with Benralizumab, which is approved for the treatment of severe eosoniphilic asthma) on circulating dendritic cells in patients with severe eosinophilic asthma.